Chronic rhinosinusitis and omalizumab: eosinophils not IgE predict treatment response in real-life

Chronic rhinosinusitis and omalizumab: eosinophils not IgE predict treatment response in real-life

Background: Chronic rhinosinusitis with and without nasal polyps (CRSwNP and CRSsNP respectively) can be difficult to treat and biologics offer potential as a future therapeutic intervention. CRS and severe asthma often co-exist. Omalizumab is currently licenced for the treatment of severe allergic...

Full description

Bibliographic Details
Main Authors:	Jagdeep Sahota, Therese Bidder, Rebecca Livingston, Douglas S. Robinson, Valerie J. Lund, Matthew P. Su, Harsha H. Kariyawasam
Format:	Article
Language:	English
Published:	Stichting NASE 2018-10-01
Series:	Rhinology Online
Subjects:	omalizumab nasal polyps asthma biomarkers ige eosinophils outcomes
Online Access:	https://www.rhinologyonline.org/Rhinology_online_issues/manuscript_33.pdf

Similar Items

A challenging case of recalcitrant Hyper-IgE syndrome successfully treated with omalizumab
by: Rashid Shahid, et al.
Published: (2022-01-01)

Chronic rhinosinusitis with and without nasal polyps and asthma: Omalizumab improves residual anxiety but not depression
by: Florian Vogt, et al.
Published: (2021-03-01)

Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis
by: Nicola Lombardo, et al.
Published: (2023-12-01)

Eosinophilic Mucin Rhinosinusitis in Iranian Patients Undergoing Endoscopic Sinus Surgery
by: Jahangir Ghorbani, et al.
Published: (2018-11-01)

Omalizumab and IgE in the Control of Severe Allergic Asthma
by: Yasuhiro Gon, et al.
Published: (2022-03-01)

Results of therapy of chronic urticaria in patients with IgE-dependent and IgE-independent disease profile
by: N. N. Zhukova, et al.
Published: (2023-06-01)

Clinical feature‐based diagnosis criteria of eosinophil and non‐eosinophil chronic rhinosinusitis in Taiwan
by: Jia‐Hung Ma, et al.
Published: (2023-12-01)

Patient characteristics that can predict response to omalizumab an (Anti-IgE Antibody) for achieving better control of asthmatic patients
by: Nancy M. Abdelaty
Published: (2012-07-01)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
by: Tajiri T, et al.
Published: (2023-01-01)

Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
by: Enrico Heffler, et al.
Published: (2020-06-01)

Comparative study of clinical symptoms of chronic rhinosinusitis with nasal polyps patients
by: Jingmin Hu, et al.
Published: (2023-02-01)

Regulation of IgE activity in inhalational tolerance via formation of IgG anti-IgE/IgE immune complexes
by: Sonali J. Bracken, et al.
Published: (2018-05-01)

Anti-IgE Antibody Therapy for Japanese Cedar Pollinosis: Omalizumab Update
by: Kimihiro Okubo, et al.
Published: (2008-01-01)

Comorbidity of eosinophilic chronic rhinosinusitis in chronic eosinophilic pneumonia
by: Hiroatsu Hatsukawa, et al.
Published: (2023-11-01)

Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab
by: Reiko Ito, et al.
Published: (2014-01-01)

Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid
by: S. Morteza Seyed Jafari, et al.
Published: (2019-08-01)

Study of the effect of anti-IgE (omalizumab) on serum level of matrix metalloproteinase-9 as a marker of remodeling in severe asthmatic patients
by: Nasr Affara, et al.
Published: (2015-10-01)

Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessment
by: Adrián Urbano, et al.
Published: (2023-12-01)

Periostin is an aggravating factor and predictive biomarker of eosinophilic chronic rhinosinusitis
by: Teruyuki Sato, et al.
Published: (2023-01-01)

The pharmacological mechanisms of omalizumab in patients with very high IgE levels—Clues from studies on atopic dermatitis
by: Tse Wen Chang, et al.
Published: (2012-12-01)

Clinical Characteristics of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps in Adolescents
by: Huang CC, et al.
Published: (2023-10-01)

Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology
by: Chen Y, et al.
Published: (2024-02-01)

Omalizumab is effective in nasal polyposis with or without asthma, a real-life study
by: Tuğba Songül Tat, MD
Published: (2022-08-01)

Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma—A Romanian Perspective
by: Elena Camelia Berghea, et al.
Published: (2021-12-01)

Efficacy and use of benralizumab in patients with eosinophilic chronic rhinosinusitis
by: G.L. Fadda, et al.
Published: (2021-03-01)

Eotaxin-3 as a Plasma Biomarker for Mucosal Eosinophil Infiltration in Chronic Rhinosinusitis
by: Takechiyo Yamada, et al.
Published: (2019-02-01)

Atopic Dermatitis and its Correlation with Eosinophil Count and Serum IgE Levels - A Case Control Study
by: Swapna S. Khatu1, Nitin D. Chaudhari2, Nachiket M. Palaskar3, Aditya R. Holani4, Garima L. Balpande5, Mahak Kukreja6, Gaurav H. Khandait7 and Rajvardhan M. Bagane8
Published: (2020-12-01)

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad
by: Paolo Cameli, et al.
Published: (2020-08-01)

Effective treatment with omalizumab of a patient with spontaneous chronic urticaria and eosinophilic esophagitis
by: Eugenio Provenzano, et al.
Published: (2018-12-01)

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases
by: Mitchell M. Pitlick, MD, et al.
Published: (2022-11-01)

Self-reactive IgE and anti-IgE therapy in autoimmune diseases
by: Anna Olewicz-Gawlik, et al.
Published: (2023-01-01)

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
by: Ashkenazi M, et al.
Published: (2018-06-01)

Patient-Reported Outcomes with Benralizumab in Patients with Severe Eosinophilic Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps
by: Rory Chan, et al.
Published: (2023-03-01)

Vernal Keratoconjunctivitis: A Case of Anti-IgE Treatment with Short-Lasting Remission
by: Alessia Gatta, et al.
Published: (2020-07-01)

Differences in Clinical and Immunological Characteristics According to the Various Criteria for Tissue Eosinophilia in Chronic Rhinosinusitis With Nasal Polyps
by: Seung Koo Yang, et al.
Published: (2023-11-01)

Eosinophilic gastritis and gluten-sensitive enteropathy manifested as hypoproteinemia and treated with omalizumab: a case report
by: Zhirong Du, et al.
Published: (2024-03-01)

The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan
by: Tao Chen, et al.
Published: (2017-05-01)

Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review
by: Jun Lan, et al.
Published: (2022-05-01)

Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers – A real-life prospective study
by: Ming Zheng, MD, PhD, et al.
Published: (2022-10-01)

Serum IgE Levels and Total Eosinophil Count in Allergic Rhinitis
by: Mirza Khizar Hameed , Atif Sharif , Mahum Khizar
Published: (2021-12-01)